Key Highlights

  • BioVie (NASDAQ:BIVI) traded at USD 1.40 intraday on November 4, 2026, a fall of 19.08%, with 419.09K shares changing hands and an intraday market Capitalization near USD 11.94 million.
  • A company release dated November 4, 2026 set pricing at 2,962,500 shares at USD 1.60, paired with matching warrants at USD 1.70, which together bring in roughly USD 4.74 million gross.
  • The offering price is under the calculated prior close of USD 1.73, and the warrants create a second route to future share issuance that existing holders would have to absorb.
  • BioVie is a clinical-stage firm without an approved product, so financing terms and cash runway, rather than revenue, shape how the market reacts to each new raise.

What Drove the BioVie Move (down USD 0.33, 19.08%)

BioVie (NASDAQ:BIVI) changed hands at USD 1.40 during regular trading on November 4, 2026, a 19.08% decline. Working in reverse, the implied prior close was USD 1.73 (calculated as USD 1.40 divided by 0.8092), so the intraday loss is USD 0.33 per share. Volume of 419.09K shares ran at roughly 0.29 times the average. The company release dated November 4, 2026 disclosed pricing of a registered direct offering along with a concurrent private placement. It is the only company announcement dated November 2 to November 4, 2026 that was identified.

How the Offering Is Built

Per the company release, one healthcare-focused institutional investor agreed to purchase 2,962,500 shares of common stock, or pre-funded equivalents in place of shares, at USD 1.60 apiece. The price is characterized as at-the-market under Nasdaq rules. Through a simultaneous private placement, the same investor also obtains unregistered warrants covering up to 2,962,500 shares at an exercise price of USD 1.70. Those warrants can be exercised starting six months after issuance and lapse five and a half years after issuance. Gross proceeds total about USD 4.74 million before Placement agent fees and other expenses. Closing is anticipated on or about November 5, 2026, subject to standard conditions, and the money is earmarked for Working Capital and general corporate uses.

Dilution, Cash Needs and Small-Cap Risk

A registered direct offering puts new shares into the market at a price normally set near or beneath the most recent trade, which means each existing share represents a smaller portion of the company. Measured against the intraday market capitalization of roughly USD 11.94 million, the USD 4.74 million raise equals around 40% of that figure (simple arithmetic on two published numbers). The warrants could bring in another 2,962,500 shares if exercised, though the USD 1.70 strike is above the current quote, so they carry no immediate worth for the holder. At this size, a small number of trades can push the price around, spreads may be wide and quoted moves may reverse. None of this implies the decline will keep going.

Where Things Stand

BioVie (NASDAQ:BIVI) is off 19.08% intraday because on November 4, 2026 it priced a USD 4.74 million registered direct offering, issuing new shares at USD 1.60 and attaching warrants at USD 1.70. The transaction lengthens the cash runway but enlarges the share count, and the quote sits under the calculated prior close of USD 1.73. Investors will track the closing expected on or about November 5, 2026 and the way the proceeds get used.